Carla B. Hartman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Carla B. Hartman has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- An Matheeussen
University of Antwerp Universiteitsplein 1
1 shared publication Guy Caljon
Laboratory of Microbiology, Parasitology and Hygiene, Infla‐Med Centre of Excellence University of Antwerp Antwerp Belgium
1 shared publicationLesetja J. Legoabe
Centre of Excellence for Pharmaceutical Sciences North‐West University Potchefstroom South Africa
1 shared publication- Natascha Van Pelt
University of Antwerp Universiteitsplein 1
1 shared publication Phelelisiwe S. Dube
Centre of Excellence for Pharmaceutical Sciences North‐West University Potchefstroom South Africa
1 shared publication- Richard M. Beteck
Centre of Excellence for Pharmaceutical Sciences North‐West University Potchefstroom South Africa
1 shared publication
Latest Publications
- Open Access
- 23 February 2024
- Published by Wiley in Archiv der Pharmazie
- Vol. 357 (6) , e2300319
Novel quinoline derivatives with broad‐spectrum antiprotozoal activities
Several quinoline derivatives incorporating arylnitro and aminochalcone moieties were synthesized and evaluated in vitro against a broad panel of trypanosomatid protozoan parasites responsible for sleeping sickness (Trypanosoma brucei rhodesiense), nagana (Trypanosoma brucei brucei), Chagas disease (Trypanosoma cruzi), and leishmaniasis (Leishmania infantum). Several of the compounds demonstrated significant antiprotozoal activity. Specifically, compounds 2c, 2d, and 4i displayed submicromolar activity against T. b. rhodesiense with half‐maximal effective concentration (EC50) values of 0.68, 0.8, and 0.19 µM, respectively, and with a high selectivity relative to human lung fibroblasts and mouse primary macrophages (∼100‐fold). Compounds 2d and 4i also showed considerable activity against T. b. brucei with EC50 values of 1.4 and 0.4 µM, respectively.
- 23 February 2024
- Published by Wiley in Archiv der Pharmazie
- Vol. 357 (6) , e2300319
Open AccessNovel quinoline derivatives with broad‐spectrum antiprotozoal activities
Several quinoline derivatives incorporating arylnitro and aminochalcone moieties were synthesized and evaluated in vitro against a broad panel of trypanosomatid protozoan parasites responsible for sleeping sickness (Trypanosoma brucei rhodesiense), nagana (Trypanosoma brucei brucei), Chagas disease (Trypanosoma cruzi), and leishmaniasis (Leishmania infantum). Several of the compounds demonstrated significant antiprotozoal activity. Specifically, compounds 2c, 2d, and 4i displayed submicromolar activity against T. b. rhodesiense with half‐maximal effective concentration (EC50) values of 0.68, 0.8, and 0.19 µM, respectively, and with a high selectivity relative to human lung fibroblasts and mouse primary macrophages (∼100‐fold). Compounds 2d and 4i also showed considerable activity against T. b. brucei with EC50 values of 1.4 and 0.4 µM, respectively.